WVE - Company ID 0001631574
The table below shows Wave Life Sciences Ltd.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$187.49M | -$151.03M | -$19.43M | -$127.78M | -$88.99M | -$115.98M |
| Capital expenditure | $718.00K | $938.00K | $1.11M | $1.36M | $560.00K | $1.34M |
| Investing cash flow | -$718.00K | -$938.00K | -$1.11M | -$1.25M | -$560.00K | -$1.34M |
| Dividends paid | - | - | - |
Wave Life Sciences Ltd. reported operating cash flow of -$187.49M for fiscal year 2025. That is down 24.1% from -$151.03M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$31.93M (FY 2016) to -$187.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $488.24M | $253.89M | $132.53M | $67.19M | $55.83M | $154.54M |